Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

LEUVEN, Belgium, March 12 /PRNewswire-FirstCall/ --

- ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments that will make a real difference to patient care in a number of important therapeutic areas, is today issuing a business update and its financial results for the full year ending December 31, 2008.

During the last twelve months, ThromboGenics has made considerable progress across all aspects of its business culminating in the recent start of the Phase III clinical development program for its lead product microplasmin in back of the eye disease. The decision to start the Phase III program was based on the positive Phase II clinical results which were announced over the course of 2008.

In June 2008, ThromboGenics announced a further important corporate milestone, the signing of a high value strategic alliance with Roche for its novel anti-cancer antibody TB-403 (anti-PIGF). This deal, which generated an upfront payment of EUR30 million, has provided significant funding to allow ThromboGenics to invest in its other development programs.

The upfront payment from the Roche deal has enabled ThromboGenics to report a pre-tax profit of EUR 12.2 million in 2008.

Given its recent progress, ThromboGenics is confident that over the next eighteen months it will be able to generate significant shareholder value as it continues to maximize the value of its exciting product pipeline.

Business Highlights

Clinical Highlights

Microplasmin - Eye Disease: Positive results announced in Phase II clinical trials for back of the eye indications. Positive results were reported in ThromboGenics' Phase IIb (MIVI III) trial in patients with a number of back of the eye conditions. The trial show
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and ... to 100x better detail than the industry standard. ... light microscopy methods, it needed another medium to measure ... frame of reference because it represents the highest standard ... the earliest discovery days of Ultralight Histology was to ...
(Date:5/4/2015)... --  Tocagen Inc. , a clinical-stage immuno-oncology company, ... investigational studies were presented at the 11 th ... Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section ... Washington, D.C. In addition, Tocagen ... and continues to advance towards initiation of a ...
(Date:5/1/2015)... BETHESDA, Md. , May 1, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... on the $28.5 million second tranche of a $40 ... ("Woodford"). Woodford first invested $25 million in ... 2015, Woodford entered into an agreement with the Company ...
(Date:5/1/2015)... - Softchoice, a leading North American IT solutions and managed services ... two Cisco® Partner Summit Country awards. Cisco ... Partner of the Year for Canada ... Montreal . "We are ... at this year,s conference," said David MacDonald , Softchoice,s ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2
... CLEVELAND, Ohio and LOD, Israel, November 26 ... simulation to advance,clinical performance, announces the world-wide release ... procedure. , ... over traditional open surgery, surgeons have been slow ...
... England, November 26 Sosei,Group Corporation ("Sosei"; TSE Mothers ... out-licensed its IP and Know How,relating to the RS(+) ... based pharma company, for the treatment and prophylaxis of,malaria. ... a highly efficacious anti-malarial drug that is approved in,its ...
... Calif., Nov. 25 Beckman Coulter, Inc. (NYSE: ... that simplify, automate, and innovate complex biomedical testing, announced today ... Business Development, will present at the following conferences: , ... , , , ...
Cached Biology Technology:New Colorectal Module From Simbionix Advances Laparoscopic Cancer Treatment 2Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria 2Beckman Coulter to Present at Upcoming Healthcare Conferences 2
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... Stents that keep weakened and flabby arteries from collapsing ... stents are no longer needed -- once the arteries ... choice but to leave them in place. Prof. ... Engineering has developed a new patent-pending fiber platform that ...
... fish food is a matter of debate. A high-profile study ... percent of their carbon from trees and leaves, evidence for ... But new research from the University of Washington shows ... much richer diet for fish and other aquatic life, according ...
... Applied mathematicians dissected the morphology of the plantain ... with a saddle-like arc midsection and closely packed ripples ... fan-like shapeelastic relaxation resulting from bending during differential growthwas ... ribbons. Haiyi Liang, a postdoctoral student at Harvard,s ...
Cached Biology News:A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3The cause behind the characteristic shape of a long leaf revealed 2
sPLA2-XII Human, Rabbit Polyconal Antibody Anti-Human sPLA2-XII Antibody was raised in rabbits against Human sPLA2-XII His-Tagged Fusion Protein Antigen: The recombinant human protein sPLA-XII...
... computing power of your ValveBank system! Program ... PC computer running Windows 98, 2000, XP using ... to disk, print out program listings, then download ... simple step., EasyCode is used for programming before ...
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
Biology Products: